Show simple item record

dc.contributor.authorBettiol, Alessandra
dc.contributor.authorUrban, Maria Letizia
dc.contributor.authorDagna, Lorenzo
dc.contributor.authorCottin, Vincent
dc.contributor.authorFranceschini, Franco
dc.contributor.authorDel Giacco, Stefano
dc.contributor.authorSchiavon, Franco
dc.contributor.authorNeumann, Thomas
dc.contributor.authorLopalco, Giuseppe
dc.contributor.authorNovikov, Pavel
dc.contributor.authorBaldini, Chiara
dc.contributor.authorLombardi, Carlo
dc.contributor.authorBerti, Alvise
dc.contributor.authorAlberici, Federico
dc.contributor.authorFolci, Marco
dc.contributor.authorNegrini, Simone
dc.contributor.authorSinico, Renato Alberto
dc.contributor.authorQuartuccio, Luca
dc.contributor.authorLunardi, Claudio
dc.contributor.authorParronchi, Paola
dc.contributor.authorMoosig, Frank
dc.contributor.authorEspígol-Frigolé, Georgina
dc.contributor.authorSchroeder, Jan
dc.contributor.authorKernder, Anna Luise
dc.contributor.authorMonti, Sara
dc.contributor.authorSilvagni, Ettore
dc.contributor.authorCrimi, Claudia
dc.contributor.authorCinetto, Francesco
dc.contributor.authorFraticelli, Paolo
dc.contributor.authorRoccatello, Dario
dc.contributor.authorVacca, Angelo
dc.contributor.authorMohammad, Aladdin J
dc.contributor.authorHellmich, Bernhard
dc.contributor.authorSamson, Maxime
dc.contributor.authorBargagli, Elena
dc.contributor.authorCohen Tervaert, Jan Willem
dc.contributor.authorRibi, Camillo
dc.contributor.authorFiori, Davide
dc.contributor.authorBello, Federica
dc.contributor.authorFagni, Filippo
dc.contributor.authorMoroni, Luca
dc.contributor.authorRamirez, Giuseppe Alvise
dc.contributor.authorNasser, Mouhamad
dc.contributor.authorMarvisi, Chiara
dc.contributor.authorToniati, Paola
dc.contributor.authorFirinu, Davide
dc.contributor.authorPadoan, Roberto
dc.contributor.authorEgan, Allyson
dc.contributor.authorSeeliger, Benjamin
dc.contributor.authorIannone, Florenzo
dc.contributor.authorSalvarani, Carlo
dc.contributor.authorJayne, David
dc.contributor.authorPrisco, Domenico
dc.contributor.authorVaglio, Augusto
dc.contributor.authorEmmi, Giacomo
dc.contributor.authorEuropean EGPA Study Group
dc.date.accessioned2021-11-16T00:30:07Z
dc.date.available2021-11-16T00:30:07Z
dc.date.issued2021-08-04
dc.identifier.issn2326-5191
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330647
dc.description.abstractOBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015-2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ≤4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty-five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherWiley
dc.rightsAll rights reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectEuropean EGPA Study Group
dc.titleMepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
dc.typeArticle
prism.publicationDate2021
prism.publicationNameArthritis Rheumatol
dc.identifier.doi10.17863/CAM.78092
dcterms.dateAccepted2021-07-29
rioxxterms.versionofrecord10.1002/art.41943
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-08-04
dc.contributor.orcidJayne, David [0000-0002-1712-0637]
dc.identifier.eissn2326-5205
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-12-30
cam.orpheus.success2021-11-15 - Embargo set during processing via Fast-track
rioxxterms.freetoread.startdate2022-08-04


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record